AVPT vs BLKB

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth (23.6% YoY) and strong gross margins (74.51%), profitability remains thin with only a 0.50% net margin and weak ROE (0.67%). Analysts recommend a 'buy' with a $19.02 target, implying 51% upside, but insider selling of $89.11M over the last six months contradicts this optimism. The stock trades at a high forward P/E of 32.18, above sector averages, while recent price performance is bearish (-31.3% over 1Y), reflecting market skepticism despite improving earnings trends.

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no Altman Z-Score available to confirm safety from distress. Despite strong operating margins and recent earnings beats, the company is unprofitable overall (negative net margin and ROE), carries an extremely high debt/equity ratio of 9.93, and shows weak liquidity. Valuation multiples like a Price/Book of 24.60 appear stretched against poor profitability, while insider selling and declining revenue further undermine confidence. The stock trades below analyst targets but faces significant structural and financial headwinds.